Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent
about
The role of the ubiquitin proteasome system in cerebellar development and medulloblastomaSAG/RBX2 E3 ligase complexes with UBCH10 and UBE2S E2s to ubiquitylate β-TrCP1 via K11-linkage for degradationTargeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agentsβ-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.The mRNA-stabilizing factor HuR protein is targeted by β-TrCP protein for degradation in response to glycolysis inhibition.Skp1 in lung cancer: clinical significance and therapeutic efficacy of its small molecule inhibitorsInsulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2.Recent advances in SCF ubiquitin ligase complex: Clinical implicationsDiscrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing TwistΔ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions.CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation.Ribosomal protein S27-like regulates autophagy via the β-TrCP-DEPTOR-mTORC1 axis
P2860
Q26782159-3309A271-AA27-4792-96B5-85B3F0425712Q28818138-E6A7514E-412D-480A-AA54-801585794E31Q34260205-69EADFA3-1EE8-4536-9475-14C74396C577Q34554617-4580CA7D-C02C-4B91-BBF5-68B49CB2A375Q35137658-D3FC72AC-CBCD-4E45-AC52-90669E368066Q36481823-D75636C5-BC7C-4BA0-83A1-AC724E31AE95Q36544267-253044A0-664A-4B69-99D6-EBA9CDA0E8BBQ37354557-381F0F56-834B-42B1-9544-4B9AA88953B8Q37706977-D1C13EBA-E324-4F2A-860F-DD259BBF287FQ38828721-5FB03DBB-E737-432C-A651-AB9B5B5915B0Q39031250-0017528B-372B-4923-AAF0-1215F99EE08BQ41686942-26217C46-DD28-4A38-86B0-30E39003689FQ42331869-184C1A33-56C6-4B00-85C0-1255A92997BCQ44786986-57826CC0-473D-4040-9B38-93893385E71BQ59137907-D524CBAF-4929-4CAD-8AB2-4A7C1E617D1A
P2860
Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@ast
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@en
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@nl
type
label
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@ast
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@en
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@nl
prefLabel
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@ast
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@en
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@nl
P2093
P2860
P1433
P1476
Targeting the oncogenic E3 lig ...... ergy restriction-mimetic agent
@en
P2093
Ching-Shih Chen
Hsiao-Ching Chuang
Po-Chen Chu
Samuel K Kulp
Wen-Chun Hung
P2860
P304
P356
10.1371/JOURNAL.PONE.0047298
P407
P577
2012-01-01T00:00:00Z